Response from Infectious Diseases Society of America President Barbara D. Alexander, MD, MHS, FIDSA to the Suspension of the Johnson & Johnson COVID-19 Vaccine

 

“Today’s announcement by FDA and CDC to temporarily pause the administration of the Johnson & Johnson COVID-19 vaccine is an indication that our safety monitoring system is working. The number of cases of blood clotting that led to the suspension is extremely low. Yet out of an abundance of caution, CDC’s independent advisory committee will take an in-depth look at the data to determine whether it is safe to continue use of the Johnson & Johnson vaccine; FDA will also review the data.

It is important that the public continue to receive clear, accurate and up-to-date information, as well as answers to their questions, so that we can maintain and build trust and confidence in COVID-19 vaccines. The risk of becoming infected with COVID-19, and the potential for severe illness or death, remains a serious concern, and we urge everyone who is eligible to take the opportunity to be vaccinated with one of the currently available options.”

Barbara D. Alexander, MD, MHS, FIDSA